Patent application number | Description | Published |
20080233582 | SINGLE NUCLEOTIDE POLYMORPHISMS ASSOCIATED WITH SUSCEPTIBILITY TO CARDIOVASCULAR DISEASE - The present invention provides SNPs, polymorphic variants, and haplotypes associated with cardiovascular disease. The invention also provides methods for detecting the SNPs, polymorphic variants, and haplotypes. The invention also provides methods for determining an individual's genotype with respect to one or more polymorphisms and/or haplotypes associated with cardiovascular disease. The invention further provides methods of determining whether an individual has or is susceptible to development or occurrence of a cardiovascular disease or event. The methods are useful for providing diagnostic and/or prognostic information, selecting therapeutic regimens, etc. The invention further provides reagents and kits for practicing the methods. | 09-25-2008 |
20090093689 | METHOD FOR IDENTIFYING PREDICTIVE BIOMARKERS FROM PATIENT DATA - The invention relates to a method for developing a biomarker for the prognosis of the result of a therapeutical treatment based on data obtained in clinical studies, data remaining unchanged by therapy being subdivided into diagnostic and genomic parameters and the marker being defined by a combination of parameters. The method according to the invention is characterized by specifying the maximum number of parameters for defining the marker and thus the maximum complexity of the system from the beginning and by carrying out the search for defining parameters by sequential combination of clinical parameters (=z parameters) and/or genomic parameters (=x parameters). | 04-09-2009 |
20090138204 | Single nucleotide polymorphisms sensitively predicting adverse drug reactions (ADR) and drug efficacy - Provided are diagnostic methods and kits including oligo and/or polynucleotides or derivatives, including as well antibodies determining whether a human subject is at risk of getting adverse drug reaction after statin therapy or whether the human subject is a high or low responder or a good a or bad metabolizer of statins. The diagnostic methods and kits including antibodies determining whether a human subject is at risk for a cardiovascular disease. Also provided are polymorphic sequences and other genes and isolated polynucleotides encoding a phenotype associated (PA) gene polypeptide useful in methods to identify therapeutic agents and useful for preparation of a medicament to treat cardiovascular disease or influence drug response. | 05-28-2009 |
20090171052 | Polyelectrolyte Monolayers and Multilayers for Optical Signal Transducers - Polyelectrolyte monolayers and multilayers for coating optical signal transducers are disclosed. | 07-02-2009 |
20090208945 | Method for the Prediction of Adverse Drug Responses to Stains - The invention provides diagnostic methods and kits including oligo and/or polynucleotides or derivatives, including as well antibodies determining whether a human subject is at risk of getting adverse drug reaction after statin therapy. Still further the invention provides polymorphic sequences and other genes. The present invention further relates to isolated polynucleotides encoding a SADR gene polypeptide useful in methods to identify therapeutic agents and useful for preparation of a medicament to treat statin induced adverse drug reactions (SADR), the polynucleotide is selected from the group comprising: SEQ ID 1-35 with allelic variation as indicated in the sequences section contained in a functional surrounding like full length cDNA for SADR gene polypeptide and with or without the SADR gene promoter sequence. | 08-20-2009 |
20090208967 | Genetic Polymorphisms As Predictive Diagnostics For Adverse Drug Reactions (ADR) And Drug Efficacy - The invention provides diagnostic methods and kits including oligo and/or polynucleotides or derivatives, including as well antibodies determining whether a human subject is at risk of getting adverse drug reaction after statin therapy or whether the human subject is a high or low responder or a good a or bad metabolizer of statins. The invention provides further diagnostic methods and kits including antibodies determining whether a human subject is at risk for a cardiovascular disease. Still further the invention provides polymorphic sequences and other genes. | 08-20-2009 |
20090294677 | METHOD FOR SIGNAL INTENSITY CORRECTION IN WAVEGUIDE SENSORS - Methods are provided for enhancing the detection of analytes with waveguides by accounting for cumulative light absorptions attributable to the presence of one or more analytes in a sample as well as the waveguide material. | 12-03-2009 |
20100190169 | SINGLE NUCLEOTIDE POLYMORPHISMS PREDICTING CARDIOVASCULAR DISEASE - The present invention relates to an isolated polynucleotide encoding a Na | 07-29-2010 |
20100279429 | Method and Apparatus for Increasing the Sensitivity of a Biosensor Used in a Planar Waveguide - Systems, methods and apparatus are provided for mixing an analyte in a planar waveguide cartridge. The invention includes adding magnetic particles to an analyte containing one or more types of target molecules; inserting the analyte and magnetic particles into the cartridge; and moving a magnetic filed proximate to and around the cartridge containing the analyte and magnetic particles, wherein the movement of the magnet field causes movement in the analyte. | 11-04-2010 |
20130095496 | Soluble Quencher to reduce Background in qPCR assays - Soluble Quencher to reduce Background in qPCR assays The invention is in the field of is in the field of analytical technology. In particular, it is useful for conducting (RT-)quantitative PCR (qPCR) reactions for detection of DNA and RNA involving fluorescent probes. The distinguishing feature of the invention is to decrease the background not of an individual probe, but of all probes carrying the same fluorescent label. This is achieved by adding a soluble quenching dye to the qPCR reaction mix. The soluble quenching dye has an absorption of at least 40% of its maximal absorbance at the excitation wavelength and/or at the emission wave length of the fluorescent dye label This dye then acts as a “soluble shield” and allows to reduce the fluorescent background brought in by a large number of identically labeled probes. Depending on the nature (i.e. absorption spectrum) of the quenching dye, it is possible to selectively reduce the background of a single detection channel, while maintaining the signal strength of the other detection channels: This provides more flexibility, in case not all channels exhibit the same high background. | 04-18-2013 |